JP2022504607A5 - - Google Patents
Info
- Publication number
- JP2022504607A5 JP2022504607A5 JP2021519712A JP2021519712A JP2022504607A5 JP 2022504607 A5 JP2022504607 A5 JP 2022504607A5 JP 2021519712 A JP2021519712 A JP 2021519712A JP 2021519712 A JP2021519712 A JP 2021519712A JP 2022504607 A5 JP2022504607 A5 JP 2022504607A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024020461A JP2024040444A (ja) | 2018-10-12 | 2024-02-14 | Ｃｎｓ障害の処置において使用するための、１０位において環式基で置換された神経刺激性ステロイド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862745109P | 2018-10-12 | 2018-10-12 | |
| US62/745,109 | 2018-10-12 | ||
| PCT/US2019/055926 WO2020077255A1 (en) | 2018-10-12 | 2019-10-11 | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024020461A Division JP2024040444A (ja) | 2018-10-12 | 2024-02-14 | Ｃｎｓ障害の処置において使用するための、１０位において環式基で置換された神経刺激性ステロイド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022504607A JP2022504607A (ja) | 2022-01-13 |
| JP2022504607A5 true JP2022504607A5 (enExample) | 2022-10-11 |
| JP7671244B2 JP7671244B2 (ja) | 2025-05-01 |
Family
ID=68425315
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021519712A Active JP7671244B2 (ja) | 2018-10-12 | 2019-10-11 | Ｃｎｓ障害の処置において使用するための、１０位において環式基で置換された神経刺激性ステロイド |
| JP2024020461A Pending JP2024040444A (ja) | 2018-10-12 | 2024-02-14 | Ｃｎｓ障害の処置において使用するための、１０位において環式基で置換された神経刺激性ステロイド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024020461A Pending JP2024040444A (ja) | 2018-10-12 | 2024-02-14 | Ｃｎｓ障害の処置において使用するための、１０位において環式基で置換された神経刺激性ステロイド |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11634453B2 (enExample) |
| EP (2) | EP4321519B1 (enExample) |
| JP (2) | JP7671244B2 (enExample) |
| CN (2) | CN121045302A (enExample) |
| AR (1) | AR116695A1 (enExample) |
| AU (2) | AU2019357040B2 (enExample) |
| BR (1) | BR112021009428A2 (enExample) |
| CA (1) | CA3115805A1 (enExample) |
| DK (1) | DK3864022T3 (enExample) |
| ES (1) | ES2966055T3 (enExample) |
| IL (1) | IL282183A (enExample) |
| MX (2) | MX2021004159A (enExample) |
| TW (2) | TWI835884B (enExample) |
| WO (1) | WO2020077255A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202000008T1 (it) | 2012-01-23 | 2020-03-13 | Sage Therapeutics Inc | Formulazione di steroide neuroattivo comprendente un complesso di allopregnanolone e solfobutil eter beta-ciclodestrina |
| PL2887944T3 (pl) | 2012-08-21 | 2022-02-21 | Sage Therapeutics, Inc. | Allopregnanolon do leczenia lekoopornego stanu padaczkowego |
| CN113527400B (zh) | 2013-04-17 | 2024-06-28 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| ME03749B (me) | 2014-11-27 | 2021-04-20 | Sage Therapeutics Inc | KOMPOZICIJE I POSTUPCIZA LEČENJE POREMEĆAJA CNS-a |
| CN115974956A (zh) | 2016-08-23 | 2023-04-18 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体 |
| KR20200096596A (ko) | 2017-12-08 | 2020-08-12 | 세이지 테라퓨틱스, 인크. | Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체 |
| DK3864022T3 (da) * | 2018-10-12 | 2023-12-18 | Sage Therapeutics Inc | Neuroaktive steroider substitueret i Position 10 med en cyklisk gruppe til anvendelse til behandlingen af CNS-lidelser |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| DK0752860T3 (da) * | 1994-02-14 | 2000-11-13 | Euro Celtique Sa | Androstaner og pregnaner til allosterisk modulering af GABA-receptor |
| US5939545A (en) * | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| AP653A (en) | 1994-11-23 | 1998-07-21 | Cocensys Inc | Androstane and pregnane series for allosteric modulations of gaba receptor. |
| TR201808616T4 (tr) | 2012-12-18 | 2018-07-23 | Sage Therapeutics Inc | Nöroaktif 19-alkoksi-17-ikameli steroidler, bunların ön ilaçları ve bunları kullanan tedavi yöntemleri. |
| MX2021004492A (es) * | 2014-10-16 | 2022-12-05 | Sage Therapeutics Inc | Composiciones para el tratamiento de trastornos del snc. |
| US20220315621A1 (en) | 2017-12-22 | 2022-10-06 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| IL275562B2 (en) | 2017-12-22 | 2024-07-01 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| KR102917075B1 (ko) | 2018-02-11 | 2026-01-26 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | 스테로이드 유도체 조절제, 그의 제조 방법 및 그의 용도 |
| DK3864022T3 (da) * | 2018-10-12 | 2023-12-18 | Sage Therapeutics Inc | Neuroaktive steroider substitueret i Position 10 med en cyklisk gruppe til anvendelse til behandlingen af CNS-lidelser |
| WO2020264495A1 (en) * | 2019-06-27 | 2020-12-30 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3990468A1 (en) | 2019-06-27 | 2022-05-04 | Sage Therapeutics, Inc. | Compounds for treating cns disorders |
| IL296371A (en) | 2020-03-18 | 2022-11-01 | Sage Therapeutics Inc | Neuroactive steroids and methods of using them |
| EP4172171A1 (en) | 2020-06-24 | 2023-05-03 | Sage Therapeutics, Inc. | 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof |
-
2019
- 2019-10-11 DK DK19797472.8T patent/DK3864022T3/da active
- 2019-10-11 EP EP23197779.4A patent/EP4321519B1/en active Active
- 2019-10-11 JP JP2021519712A patent/JP7671244B2/ja active Active
- 2019-10-11 CA CA3115805A patent/CA3115805A1/en active Pending
- 2019-10-11 WO PCT/US2019/055926 patent/WO2020077255A1/en not_active Ceased
- 2019-10-11 CN CN202511082220.8A patent/CN121045302A/zh active Pending
- 2019-10-11 US US17/284,206 patent/US11634453B2/en active Active
- 2019-10-11 MX MX2021004159A patent/MX2021004159A/es unknown
- 2019-10-11 AU AU2019357040A patent/AU2019357040B2/en active Active
- 2019-10-11 AR ARP190102913A patent/AR116695A1/es unknown
- 2019-10-11 CN CN201980079330.5A patent/CN113166193B/zh active Active
- 2019-10-11 EP EP19797472.8A patent/EP3864022B1/en active Active
- 2019-10-11 BR BR112021009428-8A patent/BR112021009428A2/pt unknown
- 2019-10-11 ES ES19797472T patent/ES2966055T3/es active Active
- 2019-10-14 TW TW108136955A patent/TWI835884B/zh active
- 2019-10-14 TW TW113106814A patent/TWI886813B/zh active
-
2021
- 2021-04-08 IL IL282183A patent/IL282183A/en unknown
- 2021-04-09 MX MX2024011494A patent/MX2024011494A/es unknown
-
2023
- 2023-02-21 US US18/171,798 patent/US20240376144A9/en active Pending
-
2024
- 2024-02-14 JP JP2024020461A patent/JP2024040444A/ja active Pending
-
2025
- 2025-01-22 AU AU2025200422A patent/AU2025200422A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022510683A5 (enExample) | ||
| JP2023531517A5 (enExample) | ||
| JP2022514385A5 (enExample) | ||
| JP2023537632A5 (enExample) | ||
| RU2405774C2 (ru) | Гетероциклические ингибиторы аспартилпротеазы | |
| RU2020123151A (ru) | Антагонисты tlr7/8 и их применение | |
| JP2023119042A5 (enExample) | ||
| JP2017531020A5 (enExample) | ||
| JP2019094345A5 (enExample) | ||
| JP2012526728A5 (enExample) | ||
| JP2023518411A5 (enExample) | ||
| JP2018502891A5 (enExample) | ||
| JP2016517851A5 (enExample) | ||
| JP2019519587A5 (enExample) | ||
| JP2022538301A5 (enExample) | ||
| JP2016510043A5 (enExample) | ||
| JP2012505836A5 (enExample) | ||
| JP2017525699A5 (enExample) | ||
| JP2017533968A5 (enExample) | ||
| JP2022538300A5 (enExample) | ||
| RU2012125372A (ru) | Производные пиразола в качестве ингибиторов 11-бета-hsd1 | |
| JP2018505898A5 (enExample) | ||
| RU2005106846A (ru) | Производные бензотиазола, характеризующиеся агонистической активностью к бета-2-адренорецепторам | |
| JP2011521911A5 (enExample) | ||
| JP2003522763A (ja) | ピペラジンアミド置換基を持つオキサゾリジノンチオアミド |